Results 181 to 190 of about 75,066 (195)

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Prescribing Trends in Glucagon-Like Peptide-1 Medications Among Pregnant and Postpartum Persons. [PDF]

Obstet Gynecol
Lessard C, Cary C, In A, Steinle J, Lin BY, Kablinger AS, Grucza RA, Bello JK, Galati BM, Kimmel M, Bruno AM, Kelly JC, Xu KY.   +12 more
europepmc   +1 more source

Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes

British Journal of Pharmacology, EarlyView.
Abstract Incretin‐based therapies have gained momentum as a key strategy for reducing cardiovascular risk in individuals with obesity and/or type 2 diabetes (T2D). It remains unclear whether the cardiovascular benefits reflect a direct reduction in atherogenic lipoproteins—namely, low‐density lipoproteins (LDL), very low‐density lipoproteins (VLDL) and
Andrea Baragetti, Giuseppe Danilo Norata
wiley   +1 more source

Cardioprotective mechanisms and effects of glucagon-like peptide-1 receptor agonists in autoimmune rheumatic diseases. [PDF]

Rheumatology (Oxford)
Karacabeyli D, Lacaille D.
europepmc   +1 more source

Amylin analogues as a novel perspective in anti‐obesity therapy

British Journal of Pharmacology, EarlyView.
Abstract Public health systems face a major challenge because of the worldwide obesity epidemic. The number of obese individuals has increased dramatically and, even in Switzerland which may be considered a relatively “lean” country, the numbers are alarmingly high and have reached almost 50% of the adult population.
Thomas A. Lutz
wiley   +1 more source

Gut microbiota as a novel therapeutic target for eating disorders and obesity

British Journal of Pharmacology, EarlyView.
The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė, Victor Mathis, Emmanuel Darcq, Aurelijus Burokas, Elena Martín‐García, Rafael Maldonado   +5 more
wiley   +1 more source

The Role of Glucagon-like Peptide-1 in the Pathophysiology of Heart Failure: A Special Focus. [PDF]

Card Fail Rev
Rakisheva A, Zatsarinnyy A.
europepmc   +1 more source

Glucagon-like peptide-1 agonists usage to widen the living donor pool for liver transplantation: A novel metabolic strategy. [PDF]

World J Transplant
Alnagar A, Khan MU, Ahmad MS, Mersal M, Ayyad M, Hassan R, Noormohamed MS.   +6 more
europepmc   +1 more source

Glucagon-Like Peptide-1 Agonist vs. Placebo and Pulmonary Decline After Open-Heart Surgery: A Substudy of the GLORIOUS Randomised Clinical Trial. [PDF]

Acta Anaesthesiol Scand
Mikkelsen AD, Wiberg S, Schultz HHL, Møller-Sørensen PH, Høfsten D, Nilsson JC, Møller CH, Køber L, Hassager C, Kjærgaard J.   +9 more
europepmc   +1 more source